1. Home
  2. CNSP vs REVB Comparison

CNSP vs REVB Comparison

Compare CNSP & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNS Pharmaceuticals Inc.

CNSP

CNS Pharmaceuticals Inc.

HOLD

Current Price

$7.05

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$0.96

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNSP
REVB
Founded
2017
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
5.1M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
CNSP
REVB
Price
$7.05
$0.96
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$20.00
N/A
AVG Volume (30 Days)
10.3K
114.0K
Earning Date
11-17-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$0.83
52 Week High
$114.00
$60.48

Technical Indicators

Market Signals
Indicator
CNSP
REVB
Relative Strength Index (RSI) 48.63 42.53
Support Level $6.11 $1.03
Resistance Level $8.10 $1.20
Average True Range (ATR) 0.52 0.10
MACD 0.13 0.03
Stochastic Oscillator 47.24 34.22

Price Performance

Historical Comparison
CNSP
REVB

About CNSP CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: